Allopurinol [4-hydroxypyrazolo(3,4-d)pyrimidine], a potent inhibitor of xanthine oxidase, was given orally to patients with leukemia and lymphoma in whom marked hyperuricemia was present or was to be expected as a result of cytolytic therapy. There was a decrease in serum uric acid in each patient, and a decrease in urine uric acid excretion in each of the ten patients in whom it was measured. This was accompanied by only a moderate increase in urinary oxypurines and no evidence of renal, hematologic, gastrointestinal, or hepatic toxicity.
No takes yet. Share an insight, caveat, or question.
Irwin H. Krakoff (1965) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: